keyword
MENU ▼
Read by QxMD icon Read
search

Prostate brachytherapy

keyword
https://www.readbyqxmd.com/read/28333019/a-comparison-between-low-dose-rate-brachytherapy-with-or-without-androgen-deprivation-external-beam-radiation-therapy-with-or-without-androgen-deprivation-and-radical-prostatectomy-with-or-without-adjuvant-or-salvage-radiation-therapy-for-high-risk-prostate
#1
Jay P Ciezki, Michael Weller, Chandana A Reddy, Jeffrey Kittel, Harguneet Singh, Rahul Tendulkar, Kevin L Stephans, James Ulchaker, Kenneth Angermeier, Andrew Stephenson, Steven Campbell, Georges-Pascal Haber, Eric A Klein
PURPOSE: We compare the efficacy and toxicity among the 3 major modalities available used to treat high-risk prostate cancer (HRCaP). METHODS AND MATERIALS: From 1996 to 2012, 2557 HRCaP patients were treated: 734 received external beam radiation therapy (EBRT) with or without androgen deprivation therapy (ADT), 515 received low-dose-rate prostate brachytherapy (LDR) with or without ADT, and 1308 received radical prostatectomy (RP) with or without EBRT. Biochemical relapse-free survival (bRFS), clinical relapse-free survival (cRFS), and prostate cancer-specific mortality (PCSM) were assessed...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28333018/nationwide-multicenter-retrospective-study-on-high-dose-rate-brachytherapy-as-monotherapy-for-prostate-cancer
#2
Yasuo Yoshioka, Tadayuki Kotsuma, Akira Komiya, Shinji Kariya, Koji Konishi, Norio Nonomura, Kazuhiko Ogawa, Eiichi Tanaka, Kensaku Nishimura, Yasuyoshi Fujiuchi, Hiroshi Kitamura, Takuji Yamagami, Ichiro Yamasaki, Kazuo Nishimura, Teruki Teshima, Katsumasa Nakamura, Jun Itami
PURPOSE: To present, analyze, and discuss results of a nationwide, multicenter, retrospective study on high-dose-rate brachytherapy (HDR-BT) as monotherapy for low-, intermediate-, and high-risk prostate cancer. METHODS AND MATERIALS: From 1995 through 2013, 524 patients, 73 (14%) with low-risk, 207 (40%) with intermediate-risk, and 244 (47%) with high-risk prostate cancer, were treated with HDR-BT as monotherapy at 5 institutions in Japan. Dose fractionations were 27 Gy/2 fractions for 69 patients (13%), 45...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28332985/prostate-cancer-radiation-therapy-and-risk-of-thromboembolic-events
#3
Cecilia Bosco, Hans Garmo, Jan Adolfsson, Pär Stattin, Lars Holmberg, Per Nilsson, Adalsteinn Gunnlaugsson, Anders Widmark, Mieke Van Hemelrijck
PURPOSE: To investigate the risk of thromboembolic disease (TED) after radiation therapy (RT) with curative intent for prostate cancer (PCa). PATIENTS AND METHODS: We identified all men who received RT as curative treatment (n=9410) and grouped according to external beam RT (EBRT) or brachytherapy (BT). By comparing with an age- and county-matched comparison cohort of PCa-free men (n=46,826), we investigated risk of TED after RT using Cox proportional hazard regression models...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28327203/an-appraisal-of-analytical-tools-used-in-predicting-clinical-outcomes-following-radiation-therapy-treatment-of-men-with-prostate-cancer-a-systematic-review
#4
Elspeth Raymond, Michael E O'Callaghan, Jared Campbell, Andrew D Vincent, Kerri Beckmann, David Roder, Sue Evans, John McNeil, Jeremy Millar, John Zalcberg, Martin Borg, Kim Moretti
BACKGROUND: Prostate cancer can be treated with several different modalities, including radiation treatment. Various prognostic tools have been developed to aid decision making by providing estimates of the probability of different outcomes. Such tools have been demonstrated to have better prognostic accuracy than clinical judgment alone. METHODS: A systematic review was undertaken to identify papers relating to the prediction of clinical outcomes (biochemical failure, metastasis, survival) in patients with prostate cancer who received radiation treatment, with the particular aim of identifying whether published tools are adequately developed, validated, and provide accurate predictions...
March 21, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28325472/dosimetric-comparison-between-treatment-plans-of-patients-treated-with-low-dose-rate-vs-high-dose-rate-interstitial-prostate-brachytherapy-as-monotherapy-initial-findings-of-a-randomized-clinical-trial
#5
T Major, C Polgár, K Jorgo, G Stelczer, P Ágoston
PURPOSE: The aim of this study was to compare the dosimetry of intraoperative dose plans of prostate cancer patients treated with low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy (BT). METHODS AND MATERIALS: A randomized clinical trial was initiated at our institution to compare the results and side effects of LDR and HDR BT as monotherapy in the treatment of early, organ-confined prostate cancer patients. Eighty-seven patients were randomly assigned to receive HDR afterloading BT with one fraction of 19 Gy or permanent LDR (125)I seed BT with 145 Gy...
March 15, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28324092/association-between-choice-of-radical-prostatectomy-external-beam-radiotherapy-brachytherapy-or-active-surveillance-and-patient-reported-quality-of-life-among-men-with-localized-prostate-cancer
#6
Ronald C Chen, Ramsankar Basak, Anne-Marie Meyer, Tzy-Mey Kuo, William R Carpenter, Robert P Agans, James R Broughman, Bryce B Reeve, Matthew E Nielsen, Deborah S Usinger, Kiayni C Spearman, Sarah Walden, Dianne Kaleel, Mary Anderson, Til Stürmer, Paul A Godley
Importance: Patients diagnosed with localized prostate cancer have to decide among treatment strategies that may differ in their likelihood of adverse effects. Objective: To compare quality of life (QOL) after radical prostatectomy, external beam radiotherapy, and brachytherapy vs active surveillance. Design, Setting, and Participants: Population-based prospective cohort of 1141 men (57% participation among eligible men) with newly diagnosed prostate cancer were enrolled from January 2011 through June 2013 in collaboration with the North Carolina Central Cancer Registry...
March 21, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28323641/metal-artifacts-in-computed-tomography-for-radiation-therapy-planning-dosimetric-effects-and-impact-of-metal-artifact-reduction
#7
Drosoula Giantsoudi, Bruno De Man, Joost Verburg, Alexei Trofimov, Yannan Jin, Ge Wang, Lars Gjesteby, Harald Paganetti
A significant and increasing number of patients receiving radiation therapy present with metal objects close to, or even within, the treatment area, resulting in artifacts in computed tomography (CT) imaging, which is the most commonly used imaging method for treatment planning in radiation therapy. In the presence of metal implants, such as dental fillings in treatment of head-and-neck tumors, spinal stabilization implants in spinal or paraspinal treatment or hip replacements in prostate cancer treatments, the extreme photon absorption by the metal object leads to prominent image artifacts...
March 21, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28322857/vascular-targeted-photodynamic-therapy-with-padeliporfin-for-low-risk-prostate-cancer-treatment-mid-term-oncological-outcomes
#8
Souhil Lebdai, Pierre Bigot, Pierre-Adrien Leroux, Louis-Paul Berthelot, Pierre Maulaz, Abdel-Rahmene Azzouzi
PURPOSE: To assess the mid-term oncological outcomes of vascular-targeted photodynamic therapy with padeliporfin for low-risk prostate cancer treatment. MATERIAL AND METHODS: We prospectively assessed all patients treated with vascular-targeted photodynamic therapy for low-risk prostate cancer in our center. Patients were followed every 6 months. All patients underwent prostate biopsies 6 months post-treatment or in case of biological or clinical progression. Primary endpoint was the progression-free survival...
March 18, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28296186/changes-in-periprostatic-adipose-tissue-induced-by-5%C3%AE-reductase-inhibitors
#9
D Taussky, M Barkati, S Campeau, K Zerouali, A Nadiri, F Saad, G Delouya
There is increasing interest in periprostatic fat and its influence on prostate cancer aggressiveness. In vitro data suggest that adipose stromal/stem cells (ASCs) can increase production of cytokines and growth factors resulting in invasive growth and metastasis in prostate cancer. The objective of the study was to determine the interaction between 5α-reductase inhibitors (5ARIs) and periprostatic adipose tissue (PPAT) and factors of prostate cancer aggressiveness. In this retrospective study, we identified 61 patients treated with 5ARIs for a period of ≥12 months before undergoing radiation therapy (brachytherapy or external beam radiotherapy)...
March 10, 2017: Andrology
https://www.readbyqxmd.com/read/28291925/improved-prostate-delineation-in-prostate-hdr-brachytherapy-with-trus-ct-deformable-registration-technology-a-pilot-study-with-mri-validation
#10
Xiaofeng Yang, Peter J Rossi, Ashesh B Jani, Hui Mao, Zhengyang Zhou, Walter J Curran, Tian Liu
Accurate prostate delineation is essential to ensure proper target coverage and normal-tissue sparing in prostate HDR brachytherapy. We have developed a prostate HDR brachytherapy technology that integrates intraoperative TRUS-based prostate contour into HDR treatment planning through TRUS-CT deformable registration (TCDR) to improve prostate contour accuracy. In a perspective study of 16 patients, we investigated the clinical feasibility as well as the performance of this TCDR-based HDR approach. We compared the performance of the TCDR-based approach with the conventional CT-based HDR in terms of prostate contour accuracy using MRI as the gold standard...
January 2017: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28288658/prostate-cancer-treated-with-brachytherapy-an-exploratory-study-of-dose-dependent-biomarkers-and-quality-of-life
#11
Sarah O S Osman, Simon Horn, Darren Brady, Stephen J McMahon, Ahamed B Mohamed Yoosuf, Darren Mitchell, Karen Crowther, Ciara A Lyons, Alan R Hounsell, Kevin M Prise, Conor K McGarry, Suneil Jain, Joe M O'Sullivan
BACKGROUND: Low-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients with localised prostate cancer with excellent outcomes. As standard CT-based post-implant dosimetry often correlates poorly with late treatment-related toxicity, this exploratory (proof of concept) study was conducted to investigate correlations between radiation - induced DNA damage biomarker levels, and acute and late bowel, urinary, and sexual toxicity. METHODS: Twelve patients treated with (125)I PPB monotherapy (145Gy) for prostate cancer were included in this prospective study...
March 14, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28287399/a-novel-adaptive-needle-insertion-sequencing-for-robotic-single-needle-mr-guided-high-dose-rate-prostate-brachytherapy
#12
Maxence Borot de Battisti, Baudouin de Senneville, Gilion Hautvast, Dirk Binnekamp, Jan Lagendijk, Metha Maenhout, Marinus Moerland
MR-guided high-dose-rate (HDR) brachytherapy has gained increasing interest as a treatment for patients with localized prostate cancer because of the superior value of MRI for tumor and surrounding tissues localization. To enable needle insertion into the prostate with the patient in the MR bore, a single needle MR-compatible robotic system involving needle-by-needle dose delivery has been developed at our institution. Throughout the intervention, dose delivery may be impaired by: (1) sub-optimal needle positioning caused by e...
March 13, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28285790/diagnosis-and-treatment-for-clinically-localized-prostate-cancer-adherence-to-the-european-association-of-urology-clinical-guidelines-in-a-nationwide-population-based-study-gescap-group
#13
F Gómez-Veiga, A Rodríguez-Antolín, B Miñana, C Hernández, J F Suárez, J M Fernández-Gómez, M Unda, J Burgos, A Alcaraz, P Rodríguez, R Medina, J Castiñeiras, C Moreno, E Pedrosa, J M Cózar
OBJECTIVE: To assess the adherence to European Association of Urology (EAU) guidelines in the management of prostate cancer (PCa) in Spain. PATIENTS AND METHODS: Epidemiological, population-based, study including a national representative sample of 3,918 incident patients with histopathological confirmation during 2010; 95% of the patient's sample was followed up for at least one year. Diagnosis along with treatment related variables (for localized PCa -low, intermediate, high and locally-advanced by D'Amico risk stratification) was recorded...
March 9, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28284511/permanent-prostate-brachytherapy-pubic-arch-evaluation-with-diagnostic-mri
#14
Geoffrey V Martin, Thomas J Pugh, Usama Mahmood, Rajat J Kudchadker, Jihong Wang, Teresa L Bruno, Tharakeswara Bathala, Steven J Frank
PURPOSE: Pubic arch interference (PAI), when it occurs, is often a limiting factor for patients pursuing brachytherapy treatment of prostate cancer. Pre-brachytherapy pubic arch evaluation is often performed by CT or transrectal ultrasound (TRUS), but MRI has increasingly replaced these modalities for prostate cancer evaluation. The purpose of this study was to determine if staging MRI could be used to evaluate PAI and compare it with these other imaging methods. METHODS AND MATERIALS: Forty-one consecutive patients undergoing brachytherapy evaluation had pelvic MRI-, CT-, and TRUS-based brachytherapy simulation...
March 8, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28284493/dosimetric-impact-of-contouring-and-needle-reconstruction-uncertainties-in-us-ct-and-mri-based-high-dose-rate-prostate-brachytherapy-treatment-planning
#15
Susanne Rylander, Simon Buus, Erik M Pedersen, Lise Bentzen, Kari Tanderup
BACKGROUND AND PURPOSE: The purpose was to evaluate the dosimetric impact of target contouring and needle reconstruction uncertainties in an US-, CT- and MRI-based HDR prostate BT treatment planning. MATERIAL AND METHODS: US, CT, and MR images were acquired post-needle insertion in 22 HDR-BT procedures for 11 consecutive patients. Dose plans were simulated for an US-, CT- and MRI-based HDR-BT treatment planning procedure. Planning uncertainties in US- and CT-based plans were evaluated using MRI-based planning as reference...
March 8, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28274241/salvage-prostate-re-irradiation-using-high-dose-rate-brachytherapy-or-focal-stereotactic-body-radiotherapy-for-local-recurrence-after-definitive-radiation-therapy
#16
Aurélie Mbeutcha, Laurent Chauveinc, Pierre-Yves Bondiau, Marie-Eve Chand, Matthieu Durand, Daniel Chevallier, Jean Amiel, Daniel Lam Cham Kee, Jean-Michel Hannoun-Lévi
BACKGROUND: Optimal management of locally recurrent prostate cancer after definitive radiation therapy is still challenging. With the development of highly accurate radiotherapy devices, prostate salvage re-irradiation might generate lower toxicity rates than classical salvage therapies. We retrospectively evaluated the toxicity and the feasibility of a prostate re-irradiation after definitive radiation therapy failure. Two modalities were investigated: high-dose-rate brachytherapy (HDRB) on whole prostate gland and focal stereotactic radiotherapy (SBRT) using CyberKnife® linac...
March 9, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28268531/non-rigid-mri-ct-registration-for-effective-planning-of-prostate-brachytherapy
#17
I Hamdan, G Dardenne, J Bert, D Visvikis
Prostate brachytherapy is an intraoperative radiotherapy technique for irradiating prostate tumors by placing radioactive sources inside the prostate. CT image is used to calculate a personalized dose distribution (PDD) while the MRI is used to visualize the tumor and the organs at risk. Therefore, a registration of preoperative MRI and CT is essential since it could improve the overall precision of the treatment planning, the placement of radioactive sources inside the prostate as well as the visualization of the dose distribution with respect to the tumor...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28265239/determination-of-dosimetric-parameters-for-shielded-153-gd-source-in-prostate-cancer-brachytherapy
#18
Mahdi Ghorbani, Benyamin Khajetash, Najmeh Ghatei, Mohammad Mehrpouyan, Ali S Meigooni, Ramin Shahraini
BACKGROUND: Interstitial rotating shield brachytherapy (I-RSBT) is a recently developed method for treatment of prostate cancer. In the present study TG-43 dosimetric parameters of a (153)Gd source were obtained for use in I-RSBT. MATERIALS AND METHODS: A (153)Gd source located inside a needle including a Pt shield and an aluminum window was simulated using MCNPX Monte Carlo code. Dosimetric parameters of this source model, including air kerma strength, dose rate constant, radial dose function and 2D anisotropy function, with and without the shields were calculated according to the TG-43 report...
March 1, 2017: Radiology and Oncology
https://www.readbyqxmd.com/read/28263130/improving-prostate-cancer-care-collaboratively-a-multidisciplinary-formal-consensus-based-approach
#19
Andrew Loblaw, Jack Barkin, Roger Buckley, Hans Chung, John Kell, Rajiv Singal, Jeff Spodek, Danny Vesprini, Stanley Flax
INTRODUCTION: There are numerous standard treatment options for men diagnosed with localized prostate cancer. Multidisciplinary consultation before decision-making is a consensus- and quality-based objective in Ontario. With the goals of working together more collaboratively and to provide higher quality information for patients at the time of decision-making, a prostate cancer community partnership consensus (PCPC) panel was formed among six partnering centers in the Greater Toronto Area...
February 2017: Canadian Journal of Urology
https://www.readbyqxmd.com/read/28262473/androgen-suppression-combined-with-elective-nodal-and-dose-escalated-radiation-therapy-the-ascende-rt-trial-an-analysis-of-survival-endpoints-for-a-randomized-trial-comparing-a%C3%A2-low-dose-rate-brachytherapy-boost-to-a%C3%A2-dose-escalated-external-beam-boost-for
#20
W James Morris, Scott Tyldesley, Sree Rodda, Ross Halperin, Howard Pai, Michael McKenzie, Graeme Duncan, Gerard Morton, Jeremy Hamm, Nevin Murray
PURPOSE: To report the primary endpoint of biochemical progression-free survival (b-PFS) and secondary survival endpoints from ASCENDE-RT, a randomized trial comparing 2 methods of dose escalation for intermediate- and high-risk prostate cancer. METHODS AND MATERIALS: ASCENDE-RT enrolled 398 men, with a median age of 68 years; 69% (n=276) had high-risk disease. After stratification by risk group, the subjects were randomized to a standard arm with 12 months of androgen deprivation therapy, pelvic irradiation to 46 Gy, followed by a dose-escalated external beam radiation therapy (DE-EBRT) boost to 78 Gy, or an experimental arm that substituted a low-dose-rate prostate brachytherapy (LDR-PB) boost...
November 24, 2016: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
83387
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"